Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 19Terminated 3Recruiting 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 19Burkitt Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Lymphoma 7Neoplasms 5Lymphoma, Non-Hodgkin 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Leukemia, Biphenotypic, Acute 3Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Ovarian Neoplasms 2Myasthenia Gravis 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1

Interventions

Rituximab 22Lenalidomide 13orelabrutinib 12obinutuzumab 11Cyclophosphamide 9zanubrutinib 8fludarabine 7venetoclax 5Magnetic Resonance Spectroscopy 5Bendamustine Hydrochloride 5pirtobrutinib 4Specimen Handling 4Biopsy 4fludarabine phosphate 3Whole-Body Irradiation 2Vincristine 2Stem Cell Transplantation 2Prednisone 2Mycophenolic Acid 2CT-P10 2Automobiles 2treosulfan 1tafasitamab 1polatuzumab vedotin 1pemigatinib 1loncastuximab tesirine 1ibrutinib 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell, Marginal Zone × Prednisone × Clear all
NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

The Lymphoma Academic Research Organisation

Phase 3 Recruiting
260 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06700798 2025-06-17

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
90 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡